⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10647140 | 0.69 | — | — | |
| SCHEMBL6154657 | 0.60 | — | — | |
| SCHEMBL1702448 | 0.55 | — | — | |
| SCHEMBL4868723 | 0.54 | — | — | |
| Hydrochloric Acid SCHEMBL7932129 | 0.51 | — | — | |
| SCHEMBL5888231 | 0.45 | — | — | |
| SCHEMBL1300603 | 0.40 | — | — | |
| SCHEMBL2362493 | 0.40 | KDM4E (0.41) | — | |
| SCHEMBL17900003 | 0.39 | — | — | |
| SCHEMBL121778 | 0.37 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105745202-A | Novel 2,6-diaminopyrimidine derivative | 卡尔那生物科学株式会社 | 2016-07-06 | — | — | CN | claimed |
| EP-4536217-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | Fleurir Abx LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-118121707-A | Pharmaceutical composition for preventing and treating mental retardation, infection, metabolic syndrome, oral disease, osteoporosis and cancer | 林萧水银 | 2024-06-04 | — | — | CN | disclosed |
| US-20230398101-A1 | Co-agents as Therapy Against Anaerobic Pathogens | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023239822-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-103946224-A | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, their manufacture and their use as antiviral active substances | DRITTE PATENTPORTFOLIO BETEILI | 2014-07-23 | — | — | CN | disclosed |
| CN-103702989-A | Novel compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA | 2014-04-02 | — | — | CN | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2006033703-A1 | IMIDAZO[4,5-D]PYRIMIDINES, THEIR USES AND METHODS OF PREPARATION | GILEAD SCIENCES, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060052602-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1556140-A2 | NOVEL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | SYNTA PHARMACEUTICALS CORP. | 2004-10-07 | — | — | US | disclosed |
| WO-2004035740-A2 | AROMATIC BICYCLIC HETEROCYLES TO MODULATE 1L - 12 PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0831855-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5654286-A | Nucleotides for topical treatment of psoriasis, and methods for using same | HOSTETLER KARL Y (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | disclosed |